Salinomycin Suppresses LRP6 Expression and Inhibits Both Wnt/β-catenin and mTORC1 Signaling in Breast and Prostate Cancer Cells

Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells

(2014) Wenyan Lu et al.   CELLULAR SIGNALLING

Role of the Rap2/TNIK kinase pathway in regulation of LRP6 stability for Wnt signaling

(2013) Dong-Seok Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Caveolin-1-LRP6 Signaling Module Stimulates Aerobic Glycolysis in Prostate Cancer

(2013) S. A. Tahir et al.   CANCER RESEARCH

Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities

(2013) Shuang Zhou et al.   CURRENT MEDICINAL CHEMISTRY

Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of rapamycin complex 1 (mTORC1) in mice and zebrafish

(2013) A. J. Valvezan et al.   Disease Models & Mechanisms

AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity

(2013) H. T. Kwan et al.   PLoS One

The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/β-Catenin Signaling in Cancer Cells

(2013) Cuihong Lin et al.   PLoS One

Wnt/β-Catenin Signaling and Disease

(2012) Hans Clevers et al.   CELL

Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells

(2012) Wenyan Lu et al.   CELLULAR SIGNALLING

Drugging Wnt signalling in cancer

(2012) Paul Polakis   EMBO JOURNAL

N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis

(2012) Wen Liu et al.   EMBO Molecular Medicine

Low Density Lipoprotein (LDL) Receptor-related Protein 6 (LRP6) Regulates Body Fat and Glucose Homeostasis by Modulating Nutrient Sensing Pathways and Mitochondrial Energy Expenditure

(2012) Wenzhong Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Salinomycin as a Drug for Targeting Human Cancer Stem Cells

(2012) Cord Naujokat et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner

(2012) Huai-Xiang Hao et al.   NATURE

Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors

(2012) Bon-Kyoung Koo et al.   NATURE

Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways

(2012) Jian Huang et al.   NATURE MEDICINE

Upregulation of the Wnt Co-Receptor LRP6 Promotes Hepatocarcinogenesis and Enhances Cell Invasion

(2012) Edmund Kwok-Kwan Tung et al.   PLoS One

Salinomycin - A New Cancer Drug Candidate

(2011) Adam Huczynski   Chemical Biology & Drug Design

Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo

(2011) Cuihong Lin et al.   FEBS LETTERS

The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer

(2011) Taj D. King et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

FZD7 has a critical role in cell proliferation in triple negative breast cancer

(2011) L Yang et al.   ONCOGENE

Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway

(2011) Wenyan Lu et al.   PLoS One

Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells

(2011) Desheng Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mesd Is a Universal Inhibitor of Wnt Coreceptors LRP5 and LRP6 and Blocks Wnt/β-Catenin Signaling in Cancer Cells

(2010) Wenyan Lu et al.   BIOCHEMISTRY

Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation

(2010) Chan Gao et al.   NATURE CELL BIOLOGY

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies

(2010) Yan Gong et al.   PLoS One

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

(2010) S. A. Ettenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy

(2010) C.-C. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging

(2009) Rogerio M. Castilho et al.   Cell Stem Cell

Depletion of mammalian target of rapamycin (mTOR) via siRNA mediated knockdown leads to stabilization ofβ-catenin and elicits distinct features of cardiomyocyte hypertrophy

(2009) Marco Hagenmueller et al.   FEBS LETTERS

The Wnt Co-Receptor Lrp6 Is Required for Normal Mouse Mammary Gland Development

(2009) Charlotta Lindvall et al.   PLoS One

R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression

(2008) Wenyan Lu et al.   FEBS LETTERS

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc 716 mice

(2008) T. Fujishita et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA